University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 9L-12-2


An Open Label, Randomized (2:1) Phase IIB Study of Dasatinib vs. Imatinib in Patients with Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy with 400 mg Imatinib.

Type: Cancer Therapy
Phase: Phase II
Status: Open to Accrual
Treatments: Chemotherapy: Systemic
Randomized: Yes
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Casey O Connell, M.D.
Other Trial Staff:  Christine Duran, D.M., Melissa Peralta, D.M., Sondra Ortiz, R.N., Teresa Olea, R.N.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.